KRAS and cancer: This is also consistent with the highly biased pattern of KRAS amplification in cancer compared to the other isoforms [19], suggesting higher levels of KRAS are more often hitting the sweet-spot, whereas amplification of the other isoforms remains insufficient in most contexts.